Study | Design | Condition | Treatment | Dose and time | Number of patients (PP) | Mean age (SD) or age range |
---|---|---|---|---|---|---|
Aldashev AA, Thorax , 2005 [[26]] | R, DB, PC | HAPH | S | 25 mg x 3/die | 9S versus 8P | 61 (8) |
100 mg x 3/die 12 weeks | 5S versus 8P | |||||
Amin A, Congest Heart Fail , 2013 [[38]] | R, DB, PC | HFrEF | S | 25 mg x 2/die - >2 weeks | 53S versus 51P | S: 51.29 (14.80) |
Then | ||||||
50 mg x 3/die - >10 weeks | P: 50.61 (4.18) | |||||
Andersen MJ, Circulation , 2013 [[10]] | R, DB, PC | Diastolic Dysfunction after MI | S | 40 mg x 3/die 9 weeks | 34S versus 33P | S: 63 (8) |
P: 62 (7) | ||||||
Badesch, J Rheumatol , 2007 [[27]] | R, DB, PC | PAH-CTD | S | 20 mg x 3/die | 21 S | S: 52 (15) |
40 mg x 3/die | 20 S | 50 (15) | ||||
80 mg x 3/die | 19 S | 54 (14) | ||||
12 weeks | 22 P | P: 56 (14) | ||||
Behling A, J Cardiac Fail , 2008 [[23]] | R, DB, PC | CHF | S | 50 mg x 3/die | 11S versus 8P | S: 45 (12) |
4 weeks | P: 53 (11) | |||||
Bharani A, Indian Heart J , 2007 [[28]] | R, DB, PC | PAH due to congenital left to right shunt | T | 20 mg x 3 | 8 T - P | 28 (9.38) |
CO (wo:2 wks) | 4 weeks | |||||
Bocchio M, Atherosclerosis , 2008 [[33]] | R, DB, PC | ED VRF | T | 20 mg every other day | 18 T versus 18P | T: 52.05 (8.98) |
12 weeks | P: 49.61 (12.68) | |||||
Galiè N, NEJM , 2005 [[2]] | R, DB, PC | PAH | S | 20 mg x 3/die | 65 S | S: 47 (14) |
40 mg x 3/die | 63 S | 51 (15) | ||||
80 mg x 3/die | 65 S | 48 (18) | ||||
12 weeks | 65 P | P: 49 (17) | ||||
Giannetta E, Circulation , 2012 [[11]] | R, DB, PC | Diabetic Cardiomyopathy | S | 25 + 25+ 50 mg/die | 29S versus 25P | S: 60.7 (7.6) |
3 months | P: 60.2 (8.3) | |||||
Goldberg DJ, Circulation , 2011 [[36]] | R, DB, PC | CHD after Fontan Operation | S | 20 mg x 3/die | 27 S - P | 14.9 (5.1) |
CO (wo:6 wks) | 6 weeks | |||||
Goldberg, DJ Pediatr Cardiol , 2012 [[37]] | R, DB, PC | CHD after Fontan Operation | S | 20 mg x 3/die | 27 S - P | 14.9 (5.1) |
CO (wo:6 wks) | 6 weeks | |||||
Groeneweg G, BMC Muscoloskeletan disorders , 2008 [[20]] | R, DB, PC | CRPS | T | 10 mg/die - >4 weeks | 12 T versus12P | T: 39.8 (13.1) |
Then | P: 36.5 (10.6) | |||||
20 mg/die - >8 weeks | ||||||
Guazzi M, J Am Coll Cardiol , 2007 [[24]] | R, DB, PC | CHF | S | 50 mg x 3/die | 23S versus 23P | S: 62 (3) |
6 months | P: 63 (4) | |||||
Guazzi M, Circulation , 2011 [[25]] | R, DB, PC | HFpEF with PAH | S | 50 mg x 3/die | 22S versus 22P | 53-79 |
12 months | ||||||
Guazzi M, Circ Heart Fail, 2011 [[12]] | R, DB, PC | Systolic HF | S | 50 mg x 3/die | 23S versus 22P | S: 60 (4) |
12 months | P: 61 (4) | |||||
Guazzi M, Europ J Heart Failure, 2012 [[39]] | R, DB, PC | EOB in HF | S | 50 mg x 3/die | 16S versus 16P | S: 66 (8) |
12 months | P: 68 (6) | |||||
Jing, Z.C, Am J Resp Crit Care Med , 2011 [[30]] | R, DB, PC | PAH | V | 5 mg/die - >4 weeks | 43 V versus 16P | S: 32 (12) |
then | ||||||
5 mg x 2/die - >8 weeks | P: 29 (8) | |||||
Lewis GD, Circulation , 2007 [[13]] | R, DB, PC | Systolic HF and secondary PAH | S | 25 to 75 mg x 3/die | 17S versus 17P | S: 54 (4) |
12 weeks | P: 62 (3) | |||||
Lewis GD, Circ Heart Fail, 2008 [[31]] | R, DB, PC | Systolic HF and secondary PAH | S | 25 to 75 mg x 3/die | 15S versus 15P | S: 54 (4) |
12 weeks | P: 62 (3) | |||||
Rosano G MC, European Urology , 2005 [[34]] | R, DB, PC | ED VRF | T | 20 mg every other day | 16 T versus 16P | 65.4 (6.3) |
4 weeks | ||||||
Redfield MM, JAMA, 2013 [[14]] | R, DB, PC | HFpEF | S | 20 mg x 3/die - >12 weeks | 49S versus 47Pa | 62-77 |
then 60 mg x 3/die -> | 45S versus 58Pb | |||||
12 weeks | 95S versus 94Pc | |||||
Sastry BKS, JACC, 2004 [[32]] | R, DB, PC | PAH | S | 25 to 100 mg x 3/die | 20 S - P | 16-55 |
CO (wo:0) | 6 weeks | |||||
Suntharalingam J, Chest, 2008 [[40]] | R, DB, PC | CTEPH | S | 40 mg x 3/die | 8S versus 10P | S: 49.9 (13.1) |
12 weeks | P: 60 (14.4) | |||||
Van AH, J Sex Med , 2005 [[35]] | R, DB, PC | ED | V | 5 to 20 mg/die | 175 V versus 175P | V:22-76 |
12 weeks | P: 22-78 |